124 related articles for article (PubMed ID: 11436202)
1. Characterization of serum and urinary chromogranin A by size exclusion chromatography: impact on calibrator selection and urinary assay.
Tsao KC; Liu GH; Chang PY; Lin CN; Wu TL; Sun CF; Wu JT
J Clin Lab Anal; 2001; 15(4):193-8. PubMed ID: 11436202
[TBL] [Abstract][Full Text] [Related]
2. Development of a microplate assay for serum chromogranin A (CgA): establishment of normal reference values and detection of elevated CgA in malignant diseases.
Wu TL; Chang CP; Tsao KC; Sun CF; Wu JT
J Clin Lab Anal; 1999; 13(6):312-9. PubMed ID: 10633301
[TBL] [Abstract][Full Text] [Related]
3. Development of an ELISA for the detection of serum chromogranin A (CgA) in prostate and non-neuroendocrine carcinomas.
Tsao KC; Wu JT
Clin Chim Acta; 2001 Nov; 313(1-2):21-9. PubMed ID: 11694235
[TBL] [Abstract][Full Text] [Related]
4. Elevated serum chromogranin A is detectable in patients with carcinomas at advanced disease stages.
Wu JT; Erickson AJ; Tsao KC; Wu TL; Sun CF
Ann Clin Lab Sci; 2000 Apr; 30(2):175-8. PubMed ID: 10807161
[TBL] [Abstract][Full Text] [Related]
5. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones.
Nobels FR; Kwekkeboom DJ; Coopmans W; Schoenmakers CH; Lindemans J; De Herder WW; Krenning EP; Bouillon R; Lamberts SW
J Clin Endocrinol Metab; 1997 Aug; 82(8):2622-8. PubMed ID: 9253344
[TBL] [Abstract][Full Text] [Related]
6. Elevated serum chromogranin A precedes prostate-specific antigen elevation and predicts failure of androgen deprivation therapy in patients with advanced prostate cancer.
Chuang CK; Wu TL; Tsao KC; Liao SK
J Formos Med Assoc; 2003 Jul; 102(7):480-5. PubMed ID: 14517586
[TBL] [Abstract][Full Text] [Related]
7. [Clinical significant of serum chromogranin A levels for diagnosing pheochromocytoma in hypertensive patients].
Biausque F; Jaboureck O; Devos P; D'Herbomez M; Hainaut P; Carré A; Mounier-Vehier C
Arch Mal Coeur Vaiss; 2003; 96(7-8):780-3. PubMed ID: 12945223
[TBL] [Abstract][Full Text] [Related]
8. Library of sequence-specific radioimmunoassays for human chromogranin A.
Jensen TB; Hilsted L; Rehfeld JF
Clin Chem; 1999 Apr; 45(4):549-60. PubMed ID: 10102916
[TBL] [Abstract][Full Text] [Related]
9. Application of region-specific immunoassay for human chromogranin A: substantial clue for detection and measurement of chromogranin A in human plasma.
Yanaihara H; Hata M; Nishikawa Y; Hoshino M; Yanaihara N; Murai M
Regul Pept; 1999 Mar; 80(1-2):83-90. PubMed ID: 10235638
[TBL] [Abstract][Full Text] [Related]
10. Serum chromogranin-A in advanced prostate cancer.
Ferrero-Poüs M; Hersant AM; Pecking A; Brésard-Leroy M; Pichon MF
BJU Int; 2001 Nov; 88(7):790-6. PubMed ID: 11890255
[TBL] [Abstract][Full Text] [Related]
11. A new human chromogranin 'A' immunoradiometric assay for the diagnosis of neuroendocrine tumours.
Bernini GP; Moretti A; Ferdeghini M; Ricci S; Letizia C; D'Erasmo E; Argenio GF; Salvetti A
Br J Cancer; 2001 Mar; 84(5):636-42. PubMed ID: 11237384
[TBL] [Abstract][Full Text] [Related]
12. Characterisation of circulating chromogranin A in human cancer patients.
Corti A; Gasparri A; Chen FX; Pelagi M; Brandazza A; Sidoli A; Siccardi AG
Br J Cancer; 1996 Apr; 73(8):924-32. PubMed ID: 8611427
[TBL] [Abstract][Full Text] [Related]
13. Serum chromogranin A: early detection of hormonal resistance in prostate cancer patients.
Wu JT; Astill ME; Liu GH; Stephenson RA
J Clin Lab Anal; 1998; 12(1):20-5. PubMed ID: 9484665
[TBL] [Abstract][Full Text] [Related]
14. Different patterns of serum chromogranin A in patients with prostate cancer with and without undergoing hormonal therapy.
Wu JT; Wu TL; Chang CP; Tsao KC; Sun CF
J Clin Lab Anal; 1999; 13(6):308-11. PubMed ID: 10633300
[TBL] [Abstract][Full Text] [Related]
15. [Plasma chromogranin-A (CgA)--a potential marker for diagnosis, monitoring and management of prostate cancer patients].
Leibovitch I; Pinthus Y; Sella BA; Ramon J
Harefuah; 2006 Jan; 145(1):25-9, 78. PubMed ID: 16450720
[TBL] [Abstract][Full Text] [Related]
16. Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings?
Angelsen A; Syversen U; Haugen OA; Stridsberg M; Mjølnerød OK; Waldum HL
Prostate; 1997 Jan; 30(1):1-6. PubMed ID: 9018329
[TBL] [Abstract][Full Text] [Related]
17. Chromogranin A: its role in endocrine function and as an endocrine and neuroendocrine tumor marker.
Deftos LJ
Endocr Rev; 1991 May; 12(2):181-7. PubMed ID: 2070778
[TBL] [Abstract][Full Text] [Related]
18. Chromogranin A: its clinical value as marker of neuroendocrine tumours.
Nobels FR; Kwekkeboom DJ; Bouillon R; Lamberts SW
Eur J Clin Invest; 1998 Jun; 28(6):431-40. PubMed ID: 9693933
[TBL] [Abstract][Full Text] [Related]
19. [The sympathetic nervous system activity estimated on serum concentration of chromogranin A in patients with the chronic heart failure].
Rubinsztajn R
Pol Arch Med Wewn; 2001 Mar; 105(3):217-24. PubMed ID: 11680266
[TBL] [Abstract][Full Text] [Related]
20. Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours.
Baudin E; Gigliotti A; Ducreux M; Ropers J; Comoy E; Sabourin JC; Bidart JM; Cailleux AF; Bonacci R; Ruffié P; Schlumberger M
Br J Cancer; 1998 Oct; 78(8):1102-7. PubMed ID: 9792158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
